Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. carvedilol study | Health & Environmental Research Online (HERO)

Health & Environmental Research Online (HERO)

Print Feedback Export to File

This record has one attached file:

Citation
Tags

HERO ID

8271842

Reference Type

Journal Article

Title

Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. carvedilol study

Author(s)

Ramaswamy, K; ,

Year

2003

Is Peer Reviewed?

Journal

Cardiac Electrophysiology Review
ISSN: 1385-2264
EISSN: 1573-725X

Page Numbers

229-232

Language

English

PMID

14739719

DOI

10.1023/B:CEPR.0000012388.85901.1c

URL

http://link.springer.com/10.1023/B:CEPR.0000012388.85901.1c
Exit

Abstract

Atrial fibrillation (AF) is present in a significant number of patients with heart failure (HF) caused by left ventricular systolic dysfunction and is associated with increased morbidity and mortality. The deleterious interaction of AF and HF is mediated through a number of mechanisms including hemodynamic alterations and activation of the sympathetic nervous system. Beta-blockers have been shown to improve symptoms and survival in patients with HF. In addition, beta-blockers have been used in patients with AF, primarily for rate control. A retrospective analysis of the U.S. Carvedilol Heart Failure Trial demonstrated that carvedilol improves outcomes in the high-risk subgroup of patients with HF and concomitant AF.